Cardiovascular Risk Assessment
The evolution and refinement of traditional risk factors for cardiovascular disease. deGoma EM, Knowles JW, Angeli F, Budoff MJ, Rader DJ. Cardiol Rev. 2012 May;20(3):118-29.
Noninvasive atherosclerosis imaging for predicting cardiovascular events and assessing therapeutic interventions. Jacoby DS, Mohler III ER, Rader DJ. Curr Atheroscler Rep. 2004 Jan;6(1):20-6.
Hypertriglyceridemia
Demystifying triglycerides: a practical approach for the clinician. Dunbar RL, Rader DJ. Cleve Clin J Med. 2005 Aug;72(8):661-6.
Inflammation and Cardiometabolic Disease
Underdiagnosis and undertreatment of risk factors for heart disease in psoriasis:Kimball AB, Szapary P, Mrowietz U, Reich K, Langley RG, You Y, Hsu MC, Yeilding N, Rader DJ, Mehta NN. J Am Acad Dermatol. 2011 Oct;21[Epub ahead of print]
Psoriasis increases cardiovascular events. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Eur Heart J. 2010 Apr;31(8):1000-6. Epub 2009 Dec 27.
Psoriasis increases cardiovascular mortality. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Eur Heart J. 2010 Apr;31(8):1000-6. Epub 2009 Dec 27.
Psoriasis increases systemic inflammation by FDG PET/CT. Mehta NN, Yu Y, Saboury B, Foroughi N, Krishnamoorthy P, Raper A, Baer A, Antigua J, Van Voorhees AS, Torigian DA, Alavi A, Gelfand JM. Arch Dermatol. 2011 Sep;147(8):1031-9. Epub May 16.
Inflammation in the fat tissue can lead to systemic insulin resistance. Mehta NN, McGillicuddy FC, Anderson PD, Hinkle CC, Shah R, Pruscino L, Tabita-Martinez J, Sellers KF, Rickels MR, Reilly MP. 2010 Jan;59(1):172-81. Epub 2009 Sep 30.
Understanding how fat tissue relates to insulin resistance and vascular disease. Shah A, Mehta N, Reilly MP. 2008 Nov-Dec;32(6):638-44.
Metabolic syndrome (pre-diabetes) is increased in patients with psoriasis. Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, Margolis DJ, Gelfand JM. 2011 Nov 24. doi: 10.1038/jid.2011.365.[Epub ahead of print]
Lipoprotein(a)
Extremely elevated lipoprotein(a), combined hyperlipidemia, and premature atherosclerosis. deGoma EM, Wheeler MT, Marcovina SM, Ashley EA. J Clin Lipidol. 2010 Nov-Dec;4(6):543-7.
Personalized Medicine
Personalized vascular medicine: Individualizing drug therapy. deGoma EM, Rivera G, Lilly SM, Usman MH, Mohler ER 3rd. Vasc Med. 2011 Oct;16(5):391-404.
Therapies in Development
Novel HDL-directed pharmacotherapeutic strategies. deGoma EM, Rader DJ. Nat Rev Cardiol. 2011 May;8(5):266-77.
Recent developments with lipoprotein-associated phospholipase A2 inhibitors. Chauffe RJ, Wilensky RL, Mohler ER 3rd. Curr Atheroscler Rep. 2010 Jan;12(1):43-7.
Women's Health
The underappreciated impact of heart disease. deGoma EM, Karlsberg RP, Judelson DR, Budoff MJ. Womens Health Issues. 2010 Sep;20(5):299-303.